Greisa Vila1, Ann-Charlotte Akerblad2, Anders F Mattsson2, Michaela Riedl3, Susan M Webb4, Václav Hána5, Eigil H Nielsen6, Beverly M K Biller7, Anton Luger3. 1. Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: greisa.vila@meduniwien.ac.at. 2. Pfizer Endocrine Care, Sollentuna, Sweden. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. 4. IIB-Sant Pau and Service of Endocrinology, Department of Medicine, Centro de Investigación Biomédica en Enfermedades Raras (CIBER-ER Unidad 747), Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic. 6. Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. 7. Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
OBJECTIVE: To study pregnancies in a large group of patients with growth hormone deficiency and hypopituitarism; and to investigate potential factors determining pregnancy outcomes and pregnancy complications. DESIGN: We analyzed pregnancies reported in KIMS, the Pfizer International Metabolic Database, of adult patients with growth hormone deficiency treated with growth hormone. SETTING: Outpatient clinics. PATIENT(S): A total of 201 pregnancies were reported: 173 in female patients and 28 in partners of male patients. INTERVENTION(S): Growth hormone replacement therapy (GHRT) was prescribed according to the local clinical practice. MAIN OUTCOME MEASURE(S): Pregnancy outcomes (live births, gestational week at delivery, and birth weight), pregnancy complications, and their relationship to use of GHRT during pregnancy were analyzed with regression models. RESULT(S): Two-thirds of women underwent fertility treatment to achieve pregnancy. Growth hormone replacement therapy was stopped before pregnancy in 7.5% of the female patients, as soon as pregnancy was confirmed in 40.1%, and at the end of the second trimester in 24.7% of the patients, whereas 27.6% continued GHRT throughout pregnancy. Birth of a healthy child was reported in 79% of the female pregnancies, nonelective abortions occurred mainly in the first trimester, and one fetal malformation (cystic hygroma) was diagnosed in the second trimester. Pregnancy outcomes and pregnancy complications were not related to GHRT treatment patterns, method of conception, or number of additional pituitary deficiencies. CONCLUSION(S): These data on pregnancy outcomes in a large group of women with hypopituitarism revealed no relationship between GHRT regimens and pregnancy outcomes.
OBJECTIVE: To study pregnancies in a large group of patients with growth hormone deficiency and hypopituitarism; and to investigate potential factors determining pregnancy outcomes and pregnancy complications. DESIGN: We analyzed pregnancies reported in KIMS, the Pfizer International Metabolic Database, of adult patients with growth hormone deficiency treated with growth hormone. SETTING:Outpatient clinics. PATIENT(S): A total of 201 pregnancies were reported: 173 in female patients and 28 in partners of male patients. INTERVENTION(S): Growth hormone replacement therapy (GHRT) was prescribed according to the local clinical practice. MAIN OUTCOME MEASURE(S): Pregnancy outcomes (live births, gestational week at delivery, and birth weight), pregnancy complications, and their relationship to use of GHRT during pregnancy were analyzed with regression models. RESULT(S): Two-thirds of women underwent fertility treatment to achieve pregnancy. Growth hormone replacement therapy was stopped before pregnancy in 7.5% of the female patients, as soon as pregnancy was confirmed in 40.1%, and at the end of the second trimester in 24.7% of the patients, whereas 27.6% continued GHRT throughout pregnancy. Birth of a healthy child was reported in 79% of the female pregnancies, nonelective abortions occurred mainly in the first trimester, and one fetal malformation (cystic hygroma) was diagnosed in the second trimester. Pregnancy outcomes and pregnancy complications were not related to GHRT treatment patterns, method of conception, or number of additional pituitary deficiencies. CONCLUSION(S): These data on pregnancy outcomes in a large group of women with hypopituitarism revealed no relationship between GHRT regimens and pregnancy outcomes.
Authors: B G Sant' Anna; N R C Musolino; M R Gadelha; C Marques; M Castro; P C L Elias; L Vilar; R Lyra; M R A Martins; A R P Quidute; J Abucham; D Nazato; H M Garmes; M L C Fontana; C L Boguszewski; C B Bueno; M A Czepielewski; E S Portes; V S Nunes-Nogueira; A Ribeiro-Oliveira; R P V Francisco; M D Bronstein; A Glezer Journal: Pituitary Date: 2020-04 Impact factor: 4.107
Authors: Fernanda A Correa; Paulo H M Bianchi; Marcela M Franca; Aline P Otto; Rodrigo J M Rodrigues; Dani Ejzenberg; Paulo C Serafini; Edmundo Chada Baracat; Rossana P V Francisco; Vinicius N Brito; Ivo J P Arnhold; Berenice B Mendonca; Luciani R Carvalho Journal: J Endocr Soc Date: 2017-09-29
Authors: Anna Aulinas; Nicole Stantonyonge; Apolonia García-Patterson; Juan M Adelantado; Carmen Medina; Juan José Espinós; Esther López; Susan M Webb; Rosa Corcoy Journal: Pituitary Date: 2021-11-30 Impact factor: 4.107
Authors: Beverly M K Biller; Charlotte Höybye; Paul Carroll; Murray B Gordon; Anna Camilla Birkegård; Nicky Kelepouris; Navid Nedjatian; Matthias M Weber Journal: Pituitary Date: 2021-03-12 Impact factor: 4.107